Regulus Therapeutics Overview
- Year Founded
-
2007

- Status
-
Public
- Employees
-
32

- Stock Symbol
-
RGLS

- Share Price
-
$1.21
- (As of Friday Closing)
Regulus Therapeutics General Information
Description
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Contact Information
Website
www.regulusrx.comCorporate Office
- 4224 Campus Point Court
- Suite 210
- San Diego, CA 92121
- United States
Corporate Office
- 4224 Campus Point Court
- Suite 210
- San Diego, CA 92121
- United States
Regulus Therapeutics Timeline
Regulus Therapeutics Stock Performance
As of 14-Feb-2025, Regulus Therapeutics’s stock price is $1.21. Its current market cap is $79.3M with 65.5M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$1.21 | $1.21 | $0.83 - $3.79 | $79.3M | 65.5M | 465K | -$1.02 |
Regulus Therapeutics Financials Summary
As of 30-Sep-2024, Regulus Therapeutics has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 9,001 | (1,524) | (15,834) | 17,373 |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (44,258) | (30,882) | (28,117) | (27,357) |
Net Income | (41,628) | (30,037) | (28,323) | (27,808) |
Total Assets | 93,763 | 30,750 | 46,716 | 68,454 |
Total Debt | 476 | 2,389 | 6,279 | 7,090 |
Regulus Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Regulus Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Regulus Therapeutics Comparisons
Industry
Financing
Details
Regulus Therapeutics Competitors (37)
One of Regulus Therapeutics’s 37 competitors is Viridian Therapeutics, a Formerly VC-backed company based in Waltham, MA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Viridian Therapeutics | Formerly VC-backed | Waltham, MA | ||||
Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
Lineage Cell Therapeutics | Corporation | Carlsbad, CA | ||||
Mustang Bio | Formerly VC-backed | Worcester, MA |
Regulus Therapeutics Patents
Regulus Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2022361062-A1 | Methods and compositions for treatment of polycystic kidney disease | Pending | 08-Oct-2021 | ||
AU-2022360530-A1 | Methods and compositions for avoiding off-target effects | Pending | 08-Oct-2021 | ||
CA-3233014-A1 | Methods and compositions for avoiding off-target effects | Pending | 08-Oct-2021 | ||
CA-3234547-A1 | Methods and compositions for treatment of polycystic kidney disease | Pending | 08-Oct-2021 | ||
US-20240294913-A1 | Methods and compositions for treatment of polycystic kidney disease | Pending | 08-Oct-2021 | C12N15/113 |
Regulus Therapeutics Signals
Regulus Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile

Pharmaceuticals
Industry
Rank
Percentile

Biotechnology
Subindustry
Rank
Percentile

Regulus Therapeutics FAQs
-
When was Regulus Therapeutics founded?
Regulus Therapeutics was founded in 2007.
-
Where is Regulus Therapeutics headquartered?
Regulus Therapeutics is headquartered in San Diego, CA.
-
What is the size of Regulus Therapeutics?
Regulus Therapeutics has 32 total employees.
-
What industry is Regulus Therapeutics in?
Regulus Therapeutics’s primary industry is Drug Discovery.
-
Is Regulus Therapeutics a private or public company?
Regulus Therapeutics is a Public company.
-
What is Regulus Therapeutics’s stock symbol?
The ticker symbol for Regulus Therapeutics is RGLS.
-
What is the current stock price of Regulus Therapeutics?
As of 14-Feb-2025 the stock price of Regulus Therapeutics is $1.21.
-
What is the current market cap of Regulus Therapeutics?
The current market capitalization of Regulus Therapeutics is $79.3M.
-
Who are Regulus Therapeutics’s competitors?
Viridian Therapeutics, Dicerna Pharmaceuticals, Crinetics Pharmaceuticals, Lineage Cell Therapeutics, and Mustang Bio are some of the 37 competitors of Regulus Therapeutics.
-
What is Regulus Therapeutics’s annual earnings per share (EPS)?
Regulus Therapeutics’s EPS for 12 months was -$1.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »